2013 - Member of the National Academy of Medicine (NAM)
1994 - Fellow of the American Association for the Advancement of Science (AAAS)
1994 - Ho-Am Prize in Medicine, Samsung Foundation
Member of the Association of American Physicians
Waun Ki Hong spends much of his time researching Internal medicine, Pathology, Lung cancer, Cancer and Cancer research. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Endocrinology, Surgery and Oncology. His Pathology study which covers Carcinogenesis that intersects with Head and neck squamous-cell carcinoma, Retinoid, Carcinogen and Loss of heterozygosity.
His Lung cancer research is multidisciplinary, incorporating perspectives in Respiratory disease, Epidermal growth factor receptor, Case-control study, Targeted therapy and Physiology. His Cancer research also works with subjects such as
Waun Ki Hong focuses on Internal medicine, Lung cancer, Oncology, Pathology and Cancer. His research in Internal medicine intersects with topics in Gastroenterology, Endocrinology and Surgery. His Lung cancer research is multidisciplinary, relying on both Odds ratio, Respiratory disease, Cancer research, Epidermal growth factor receptor and Adenocarcinoma.
His Cancer research research also works with subjects such as
His main research concerns Internal medicine, Lung cancer, Oncology, Cancer and Pathology. Waun Ki Hong has researched Internal medicine in several fields, including Surgery and Immunology. The various areas that Waun Ki Hong examines in his Lung cancer study include Cancer research, KRAS, Carcinoma, Targeted therapy and Adenocarcinoma.
Waun Ki Hong studied Oncology and Genotype that intersect with Genetic variation. The study incorporates disciplines such as Gene expression profiling, Bioinformatics and Confidence interval in addition to Cancer. His study looks at the relationship between Pathology and fields such as Lung, as well as how they intersect with chemical problems.
Waun Ki Hong mainly focuses on Lung cancer, Cancer, Internal medicine, Oncology and Cancer research. His study in Lung cancer is interdisciplinary in nature, drawing from both Targeted therapy, KRAS, Radiology, Pneumonitis and Adenocarcinoma. The Cancer study combines topics in areas such as Gene expression, Gene expression profiling, Surgery and Pathology.
His Internal medicine study frequently intersects with other fields, such as Single-nucleotide polymorphism. His Oncology study incorporates themes from Clinical endpoint, Clinical trial, Immunology, Confidence interval and Carcinoma. In his research, Dysplasia is intimately related to Gene, which falls under the overarching field of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
Gregory T Wolf;Susan Gross Fisher;Waun Ki Hong.
The New England Journal of Medicine (1991)
Head and neck cancer.
Everett E. Vokes;Ralph R. Weichselbaum;Scott M. Lippman;Waun Ki Hong.
The New England Journal of Medicine (1993)
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.
Waun ki Hong;Scott M. Lippman;Loretta M. Itri;Daniel D. Karp.
The New England Journal of Medicine (1990)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau.
Nature Medicine (2000)
Recent Advances in Chemoprevention of Cancer
Waun Ki Hong;Michael B. Sporn.
13-cis-retinoic acid in the treatment of oral leukoplakia.
W K Hong;J Endicott;L M Itri;W Doos.
The New England Journal of Medicine (1986)
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
J. A. Roth;D. Nguyen;D. D. Lawrence;B. L. Kemp.
Nature Medicine (1996)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang;Junya Fujimoto;Jianhua Zhang;David C. Wedge.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: